Evgeny Kopyltsov
Impact in
-
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Papers in
-
- Prostate Cancer Treatment and Research 11
- Renal cell carcinoma treatment 9
- Prostate Cancer Diagnosis and Treatment 2
- Surgery 14
- Bladder and Urothelial Cancer Treatments 14
- Co-authors
- Neal D. Shore (3 shared papers)Heikki Joensuu (3 shared papers)Maha Hussain (1 shared paper)Cora Nanette Sternberg (1 shared paper)Iris Kuss (1 shared paper)Fred Saad (4 shared papers)Matthew Robert Smith (1 shared paper)Felipe José Silva Melo Cruz (1 shared paper)
- Journals
- Annals of Oncology (6 papers)Journal of Clinical Oncology (5 papers)The Lancet Oncology (4 papers)European Urology (3 papers)New England Journal of Medicine (2 papers)
- Partner nations
- United StatesRussiaFrance
In The Last Decade
Evgeny Kopyltsov
33 papers receiving 4.6k citations
Evgeny Kopyltsov's Hit Papers
Peers
Comparison fields: 5 of 78
- Pulmonary and Respiratory Medicine 2.1k
- Oncology 1.2k
- Surgery 1.3k
- Cancer Research 125
- Statistics and Probability 71
Countries citing papers authored by Evgeny Kopyltsov
This map shows the geographic impact of Evgeny Kopyltsov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgeny Kopyltsov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgeny Kopyltsov more than expected).
Fields of papers citing papers by Evgeny Kopyltsov
This network shows the impact of papers produced by Evgeny Kopyltsov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgeny Kopyltsov. The network helps show where Evgeny Kopyltsov may publish in the future.
Co-authors
The 25 scholars most cited alongside Evgeny Kopyltsov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1353 |
| 2 | Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 1096 |
| 3 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 408 |
| 4 | Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma Hit paper breakdown → | 2017 | 305 |
| 5 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 248 |
| 6 | Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial Hit paper breakdown → | 2023 | 147 |
| 7 | Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Hit paper breakdown → | 2022 | 138 |
| 8 | 2021 | 127 | |
| 9 | 2015 | 126 | |
| 10 | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Hit paper breakdown → | 2023 | 124 |
| 11 | 2016 | 112 | |
| 12 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Hit paper breakdown → | 2024 | 99 |
| 13 | Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial Hit paper breakdown → | 2024 | 77 |
| 14 | 2023 | 56 | |
| 15 | 2021 | 45 | |
| 16 | 2022 | 40 | |
| 17 | 2016 | 34 | |
| 18 | 2023 | 30 | |
| 19 | 2023 | 26 | |
| 20 | 2023 | 23 |
About Evgeny Kopyltsov
Evgeny Kopyltsov is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Urology, Endocrinology, Diabetes and Metabolism and Oncology, having authored 35 papers that have together received 4.7k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (14 papers), Prostate Cancer Treatment and Research (11 papers), Renal cell carcinoma treatment (9 papers), Prostate Cancer Diagnosis and Treatment (2 papers), Chemotherapy-induced cardiotoxicity and mitigation (1 paper), Urinary Bladder and Prostate Research (1 paper), PARP inhibition in cancer therapy (1 paper) and Hormonal and reproductive studies (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.1k citations), Oncology (1.2k citations), Surgery (1.3k citations), Cancer Research (125 citations) and Statistics and Probability (71 citations). Evgeny Kopyltsov has collaborated with scholars based in United States, Russia and France. Frequent co-authors include Neal D. Shore, Heikki Joensuu, Maha Hussain, Cora Nanette Sternberg, Iris Kuss, Fred Saad, Matthew Robert Smith, Felipe José Silva Melo Cruz, Karim S. Fizazi and Bertrand F. TOMBAL. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, The Lancet Oncology, European Urology and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.